Patient P-01615

Synthetic patientNBL-101 · Day 115 · 65–74 · F · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Unstable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

91%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 45 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 59 GI-04 recommended — GI Support Protocol GI-04
Day 60 Patient accepted — Started GI-04 in the companion
Day 68 No meaningful change — GI Support Protocol GI-04
Day 71 ME-01 recommended — Monitoring Escalation ME-01
Day 72 Patient accepted — Started ME-01 in the companion
Day 75 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days

Inflammatory activity+7
GI instability+6
Treatment adherence+6
Nutritional resilience+3

What helped?

GI Support Protocol GI-04Day 59
Result: no meaningful change
Monitoring Escalation ME-01Day 71
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

65%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 72
- WearableHRV 33 ms, trending down
Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 73 and rising
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑45
- WearableResting HR 84 bpm
- Wearable300 steps/day
Drug metabolism and exposure ↑20
- BloodToxicity index 59

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.4 · butyrate capacity 46/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 29 ms
Sleep: 6.8 h
Steps: 417
Resting HR: 84 bpm

Daily log: GI score 73, nutritional resilience 34, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01720	57%	S14	NP-02	improved	47
P-01728	55%	S14	SC-12	improved	41
P-01531	51%	S14	ME-01	improved	51
P-01612	50%	S14	ME-01	improved	51
P-01736	50%	S03	ME-01	improved	46
P-01810	47%	S05	NP-02	improved	43
P-01605	46%	S14	ME-01	improved	41
P-01656	46%	S14	ME-01	improved	41
P-01412	45%	S14	NP-02	improved	49
P-01801	45%	S14	SC-12	improved	42
P-01739	44%	S14	ME-01	improved	44
P-01751	44%	S14	ME-01	improved	48